Literature DB >> 30316776

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease.

Leslie M Shaw1, Jalayne Arias2, Kaj Blennow3, Douglas Galasko4, Jose Luis Molinuevo5, Stephen Salloway6, Suzanne Schindler7, Maria C Carrillo8, James A Hendrix9, April Ross8, Judit Illes10, Courtney Ramus10, Sheila Fifer11.   

Abstract

INTRODUCTION: The Alzheimer's Association convened a multidisciplinary workgroup to develop appropriate use criteria to guide the safe and optimal use of the lumbar puncture procedure and cerebrospinal fluid (CSF) testing for Alzheimer's disease pathology detection in the diagnostic process.
METHODS: The workgroup, experienced in the ethical use of lumbar puncture and CSF analysis, developed key research questions to guide the systematic review of the evidence and developed clinical indications commonly encountered in clinical practice based on key patient groups in whom the use of lumbar puncture and CSF may be considered as part of the diagnostic process. Based on their expertise and interpretation of the evidence from systematic review, members rated each indication as appropriate or inappropriate.
RESULTS: The workgroup finalized 14 indications, rating 6 appropriate and 8 inappropriate. DISCUSSION: In anticipation of the emergence of more reliable CSF analysis platforms, the manuscript offers important guidance to health-care practitioners and suggestions for implementation and future research.
Copyright © 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; Alzheimer's disease pathology; Amyloid PET; CSF Aβ-42, diagnostic utilities; MCI; Modified Delphi; PICOTS (population, interventions, comparisons, outcomes, timing, and settings) framework; SCD; p-tau181; t-tau, LP

Mesh:

Substances:

Year:  2018        PMID: 30316776     DOI: 10.1016/j.jalz.2018.07.220

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  51 in total

Review 1.  Biomarkers for neurodegenerative diseases.

Authors:  Oskar Hansson
Journal:  Nat Med       Date:  2021-06-03       Impact factor: 53.440

Review 2.  Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice.

Authors:  Leslie M Shaw; Magdalena Korecka; Michal Figurski; Jon Toledo; David Irwin; Ju Hee Kang; John Q Trojanowski
Journal:  J Appl Lab Med       Date:  2020-01-01

3.  Biomarkers of Alzheimer Disease.

Authors:  Melissa M Budelier; Randall J Bateman
Journal:  J Appl Lab Med       Date:  2020-01-01

4.  Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.

Authors:  June Kaplow; Manu Vandijck; Julia Gray; Michio Kanekiyo; Els Huyck; C J Traynham; Rianne Esquivel; Anne M Fagan; Johan Luthman
Journal:  Alzheimers Dement       Date:  2020-01       Impact factor: 21.566

Review 5.  Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers.

Authors:  Michelle M Mielke
Journal:  J Appl Lab Med       Date:  2020-01-01

6.  In vivo detection of beta-amyloid at the nasal cavity and other skull-base sites: a retrospective evaluation of ADNI1/GO.

Authors:  Anish Kapadia; Prarthana Desai; Adam Dmytriw; Pejman Maralani; Chris Heyn; Sandra Black; Sean Symons
Journal:  Ann Nucl Med       Date:  2021-04-12       Impact factor: 2.668

Review 7.  Tau proteins in blood as biomarkers of Alzheimer's disease and other proteinopathies.

Authors:  Federico Verde
Journal:  J Neural Transm (Vienna)       Date:  2022-02-17       Impact factor: 3.575

8.  A Neurologist's Practical Approach to Cognitive Impairment.

Authors:  Philip W Tipton; Gregory S Day; Neill Graff-Radford
Journal:  Semin Neurol       Date:  2021-11-26       Impact factor: 3.420

Review 9.  2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  A Leuzy; N J Ashton; N Mattsson-Carlgren; A Dodich; M Boccardi; J Corre; A Drzezga; A Nordberg; R Ossenkoppele; H Zetterberg; K Blennow; G B Frisoni; V Garibotto; O Hansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-05       Impact factor: 9.236

10.  Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia.

Authors:  Denis Horgan; Flavio Nobili; Charlotte Teunissen; Timo Grimmer; Dinko Mitrecic; Laurence Ris; Zvezdan Pirtosek; Chiara Bernini; Antonio Federico; Daniel Blackburn; Giancarlo Logroscino; Nikos Scarmeas
Journal:  Biomed Hub       Date:  2020-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.